Design Therapeutics (DSGN) News Today $6.25 +0.26 (+4.34%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Deepa Prasad Sells 3,806 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) StockDecember 20 at 9:09 AM | insidertrades.comDesign Therapeutics (NASDAQ:DSGN) Stock Quotes, Forecast and News SummaryDecember 20 at 8:04 AM | benzinga.comInsider Selling: Design Therapeutics, Inc. (NASDAQ:DSGN) Director Sells 3,806 Shares of StockDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) Director Deepa Prasad sold 3,806 shares of Design Therapeutics stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $6.27, for a total value of $23,863.62. Following the sale, the director now directly owns 20,000 shares of the company's stock, valued at $125,400. This trade represents a 15.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.December 19 at 7:44 PM | marketbeat.comFmr LLC Has $4.46 Million Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)Fmr LLC grew its position in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 922.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 828,665 shares of the company's stock after buying an additional 747,64December 14, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Buys 697,368 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)Frazier Life Sciences Management L.P. raised its stake in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 58.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,892,547 shares of the company's stock afterDecember 10, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Reduces Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN)Jacobs Levy Equity Management Inc. lessened its holdings in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 41.2% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 280,271 shares of the company's stock after selling 19December 9, 2024 | marketbeat.comPoint72 Asset Management L.P. Boosts Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)Point72 Asset Management L.P. raised its holdings in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 61.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,600,740 sharesDecember 8, 2024 | marketbeat.comDesign Therapeutics to Participate in Multiple Upcoming Investor ConferencesNovember 13, 2024 | globenewswire.comCautious Optimism for Design Therapeutics Amid Promising Developments and Financial ChallengesNovember 13, 2024 | markets.businessinsider.comRBC Capital Remains a Hold on Design Therapeutics (DSGN)November 9, 2024 | markets.businessinsider.comDesign Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM PortfolioNovember 7, 2024 | globenewswire.comWe're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash WiselyNovember 6, 2024 | finance.yahoo.comDesign Therapeutics (NASDAQ:DSGN) Stock, Short Interest ReportOctober 12, 2024 | benzinga.comPoint72 Asset Management L.P. Buys 397,285 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)Point72 Asset Management L.P. increased its stake in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 66.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 990,801 shares of the company's stock after purchasing an additional 397,285 sharesOctober 3, 2024 | marketbeat.comAlmitas Capital LLC Has $4.20 Million Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)Almitas Capital LLC increased its stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 22.1% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,253,248 shares of the company's stock after acquiring an additional 227,18September 29, 2024 | marketbeat.comAcadian Asset Management LLC Raises Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)Acadian Asset Management LLC lifted its holdings in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 44.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 583,160 shares of the company'sSeptember 15, 2024 | marketbeat.comDesign Therapeutics to Participate in the 2024 Cantor Global Healthcare ConferenceSeptember 10, 2024 | finance.yahoo.comDesign Therapeutics (NASDAQ:DSGN) Stock Price Up 4.4%Design Therapeutics (NASDAQ:DSGN) Shares Up 4.4%September 10, 2024 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Sees Large Drop in Short InterestDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) saw a significant decrease in short interest in August. As of August 15th, there was short interest totalling 2,940,000 shares, a decrease of 17.4% from the July 31st total of 3,560,000 shares. Approximately 9.2% of the company's shares are sold short. Based on an average daily trading volume, of 187,300 shares, the short-interest ratio is currently 15.7 days.August 31, 2024 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Up 16.7% in JulyDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totalling 3,560,000 shares, a growth of 16.7% from the July 15th total of 3,050,000 shares. Based on an average daily volume of 205,600 shares, the days-to-cover ratio is currently 17.3 days. Approximately 10.7% of the shares of the company are short sold.August 18, 2024 | marketbeat.comVanguard Group Inc. Raises Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)Vanguard Group Inc. raised its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 29.0% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,285,962 shares of the company's stock after buying an additAugust 18, 2024 | marketbeat.comWith 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investorsAugust 17, 2024 | finance.yahoo.comArsani William Sells 814,874 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) StockAugust 13, 2024 | insidertrades.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Director Sells 814,874 SharesDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) Director Arsani William sold 814,874 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $4.25, for a total value of $3,463,214.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.August 12, 2024 | marketbeat.comGenerative AI vs. cancer: Absci partners with Memorial Sloan Kettering for new therapeuticsAugust 12, 2024 | msn.comFY2024 EPS Estimates for Design Therapeutics, Inc. (NASDAQ:DSGN) Boosted by Leerink PartnrsDesign Therapeutics, Inc. (NASDAQ:DSGN - Free Report) - Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for Design Therapeutics in a report issued on Monday, August 5th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.87) per shareAugust 8, 2024 | marketbeat.comDesign Therapeutics' (DSGN) "Sector Perform" Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reaffirmed a "sector perform" rating and issued a $4.00 target price on shares of Design Therapeutics in a research report on Tuesday.August 6, 2024 | marketbeat.comDesign Therapeutics (NASDAQ:DSGN) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPSDesign Therapeutics (NASDAQ:DSGN - Get Free Report) posted its earnings results on Monday. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.02.August 6, 2024 | marketbeat.comDesign Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ PortfolioAugust 5, 2024 | globenewswire.comAcadian Asset Management LLC Boosts Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)Acadian Asset Management LLC raised its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 123.3% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 403,546 shares of the company's stock afJuly 25, 2024 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of "Hold" from BrokeragesDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has received a consensus rating of "Hold" from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and one has issued a buy recommendatJuly 23, 2024 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Hold" by BrokeragesDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has earned a consensus recommendation of "Hold" from the six analysts that are currently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the compJune 28, 2024 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Given Consensus Rating of "Hold" by AnalystsDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has been given an average recommendation of "Hold" by the six ratings firms that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and one has given a buy recomJune 3, 2024 | marketbeat.comDesign Therapeutics, Inc.: Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesMay 25, 2024 | finanznachrichten.deThe 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit GainsMay 22, 2024 | investorplace.comLarimar stock rallies 24% on FDA removal of partial clinical holdMay 20, 2024 | msn.comDesign Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic ReviewMay 10, 2024 | finance.yahoo.comHold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial ReviewMay 10, 2024 | markets.businessinsider.comDSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024May 9, 2024 | msn.comDesign Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesMay 8, 2024 | globenewswire.comPiper Sandler Upgrades Design Therapeutics (DSGN)May 7, 2024 | msn.comDesign Therapeutics climbs as Piper Sandler upgrades on pipelineMay 7, 2024 | msn.comBuy Rating Justified by Design Therapeutics’ Innovative Pipeline and Solid FinancialsMay 7, 2024 | markets.businessinsider.comPiper Sandler Upgrades Design Therapeutics (NASDAQ:DSGN) to "Overweight"Piper Sandler upgraded Design Therapeutics from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $6.00 to $12.00 in a report on Tuesday.May 7, 2024 | marketbeat.comDesign Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceMay 7, 2024 | globenewswire.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Sees Significant Growth in Short InterestDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 2,390,000 shares, a growth of 7.2% from the March 31st total of 2,230,000 shares. Based on an average daily trading volume, of 258,100 shares, the short-interest ratio is currently 9.3 days. Approximately 7.2% of the company's stock are short sold.May 1, 2024 | marketbeat.com1,029,478 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Acquired by BML Capital Management LLCBML Capital Management LLC bought a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,029,478 shares ofApril 24, 2024 | marketbeat.comIndependent Director of Design Therapeutics Picks Up 88% More StockMarch 27, 2024 | finance.yahoo.comDesign Therapeutics And 2 Other Stocks Under $5 Insiders Are BuyingMarch 26, 2024 | msn.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Director John P. Schmid Purchases 9,156 SharesMarch 26, 2024 | insidertrades.com Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Most People Are Dead Wrong. (Ad)Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years. I call it my AI Retirement Playbook. I recommend you check it out now. DSGN Media Mentions By Week DSGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DSGN News Sentiment▼0.860.60▲Average Medical News Sentiment DSGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DSGN Articles This Week▼41▲DSGN Articles Average Week Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OCUL News MESO News TVTX News NTLA News PRAX News ARVN News ARDX News DAWN News SYRE News CALT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DSGN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DSGN Stock Alerts